InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Discover the full record of transactions filed by Gano Kyle, Chief Executive Officer. Officer active across 1 companies, notably Neurocrine Biosciences INC. Aggregated, 6 disclosures have been recorded. Total volume traded: €99k. The latest transaction was disclosed on 16 January 2026 — Levée d'options. Regulator: SEC (Form 4). All data is openly available.
Declarations6 total
US$1m34,588 shares@ US$31.00180.0076% mcap80.1% of flow
Common Stock
SEC:0001567160-26-000002·
€1m34,588 shares@ €31.00180.0076% mcap40.0% of flow
Common Stock
SEC:0001567160-26-000002:0·
€49,515703 shares@ €70.43380.0003% mcap3.7% of flow
Common Stock
SEC:0001209191-22-008207·
€49,515703 shares@ €70.43380.0003% mcap1.8% of flow
Common Stock
SEC:0001209191-22-008207:0·
€216,93728,266 shares@ €7.67480.0015% mcap16.2% of flow
Common Stock
SEC:0001209191-22-002529·
€216,93728,266 shares@ €7.67480.0015% mcap8.1% of flow
Common Stock
SEC:0001209191-22-002529:0·
6 of 6 declarations
About Gano Kyle
Kyle Gano serves as Chief Executive Officer and Chief Business Development Officer at Neurocrine Biosciences Inc. He leads the company's strategic initiatives and oversees the development of new business opportunities. Kyle brings expertise in management and product development, contributing to innovation and growth at Neurocrine.
